Definitive Contract 75F40120C00158
Award Date
9/24/20
Potential Completion Date
9/28/25
Potential Value
$11M
Federal Agency
Food and Drug Administration
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
7
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award with ID 75A50124C00046 was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation, a for-profit manufacturer. The $188,446,002.15 cost-sharing contract is for the license of Cerus' proprietary Pathogen Reduction Technology (PRT) for red blood cell (RBC) components, with the goal of reducing the risk of transfusion-transmitted infections by recognized, emerging, epidemic, and endemic pathogens. This...
This firm fixed-price purchase order contract was awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The $369,384 contract is for the provision of Cerus' proprietary INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets and plasma. This pathogen reduction technology plays a critical role in reducing...
The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
This federal contract award to Cerus Corporation, a biomedical products company, is for the delivery of INTERCEPT Platelet Processing Kits. The award, valued at $232,128.00, was made by the Defense Health Agency (DHA), a component of the Department of Defense. The contract has a period of performance ending on September 30, 2027. Cerus Corporation's INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, plays a crucial role in reducing...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $14,924.64, is for the provision of INTERCEPT Blood System equipment, illuminator maintenance services, and specialized pathogen reduction technology products. The contract has a performance period ending on June 7, 2025. Cerus...
This federal contract award is for the "LYOPHILIZED PATHOGEN REDUCED CRYOPRECIPITATE (LYO-CRYO) MANUFACTURING ADVANCEMENT PROJECT," awarded to Cerus Corporation by the Office of the Secretary of Defense. The $17,791,786.00 other transaction agreement is for the development and advancement of the company's proprietary INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. Cerus Corporation is a biomedical products company...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that specializes in blood safety technologies and pathogen reduction systems. The contract, valued at $45,898.00, is for the maintenance and support of INTERCEPT Blood System illuminators, which are essential components of Cerus's proprietary pathogen reduction process for blood products. The contract has an ultimate completion date of September 26, 2027. Cerus...
This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...